The genetic and biochemical heterogeneity of this aggressive cancer with high metastatic potential and limited response to chemotherapeutic agents is associated, among other occurrences, with high frequency of mutations such as those in the BRAF, NRAS, and C-KIT genes [2]. This evidence concerns the gene BRAF and cancer.